Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Leukemia, Myeloid, Acute 69Breast Neoplasms 51Carcinoma, Non-Small-Cell Lung 29Neoplasms 27Myelodysplastic Syndromes 27Advanced Solid Tumors 27Advanced Solid Tumor 26Prostatic Neoplasms 23Stomach Neoplasms 19Recurrence 19Multiple Myeloma 19Neoplasm Metastasis 18Carcinoma, Hepatocellular 17Lung Neoplasms 16Ovarian Neoplasms 15Pancreatic Neoplasms 14Uterine Cervical Neoplasms 13Solid Tumor 13Sarcoma 13Melanoma 13Leukemia, Myelomonocytic, Chronic 13Colorectal Neoplasms 12Triple Negative Breast Neoplasms 10Small Cell Lung Carcinoma 10Lymphoma, Large B-Cell, Diffuse 10Esophageal Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Myeloproliferative Disorders 8Lymphoma, Non-Hodgkin 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7

Interventions

pembrolizumab 188Cisplatin 47Paclitaxel 45Carboplatin 44lenvatinib 31Docetaxel 23Pemetrexed 21Fluorouracil 20Capecitabine 17Gemcitabine 15Oxaliplatin 14Saline Solution 13Albumin-Bound Paclitaxel 11130-nm albumin-bound paclitaxel 10epacadostat 9Leucovorin 9Cetuximab 9olaparib 7Irinotecan 7Bevacizumab 7Etoposide 6enzalutamide 5belzutifan 5Dexamethasone 5durvalumab 4Surgical Procedures, Operative 4Radiotherapy 4Nivolumab 4trifluridine tipiracil drug combination 3spartalizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Parkinson Disease 4, Autosomal Dominant Lewy Body × Injections × Clear all
NCT04812002 2022-06-03

Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined Chemotherapy

Women's Hospital School Of Medicine Zhejiang University

Phase 2 Unknown
20 enrolled
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Gestational Trophoblastic Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡